144 related articles for article (PubMed ID: 33349149)
1. Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients.
Uchiyama K; Saito Y; Takekuma Y; Sugita J; Teshima T; Sugawara M
J Oncol Pharm Pract; 2022 Jan; 28(1):31-38. PubMed ID: 33349149
[TBL] [Abstract][Full Text] [Related]
2. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients.
van Hest RM; Doorduijn JK; de Winter BC; Cornelissen JJ; Vulto AG; Oellerich M; Löwenberg B; Mathot RA; Armstrong VW; van Gelder T
Ther Drug Monit; 2007 Jun; 29(3):353-60. PubMed ID: 17529894
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.
Zhang D; Chow DS
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):183-189. PubMed ID: 27677732
[TBL] [Abstract][Full Text] [Related]
6. Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome after Hematopoietic Cell Transplantation.
Saqr A; Carlson B; Staley C; Rashidi A; Al-Kofahi M; Kaiser T; Holtan S; MacMillan M; Young JA; Jurdi NE; Weisdorf D; Khoruts A; Jacobson PA
Transplant Cell Ther; 2022 Jul; 28(7):372.e1-372.e9. PubMed ID: 35489611
[TBL] [Abstract][Full Text] [Related]
7. [Impact of mycophenolate mofetil prophylaxis duration on acute graft-versus-host disease after haploidentical stem cell transplantation].
Sun YQ; Huang XJ; Xu LP; Zhang XH; Yan CH; Liu KY; Wang Y
Zhonghua Xue Ye Xue Za Zhi; 2018 Apr; 39(4):286-291. PubMed ID: 29779322
[No Abstract] [Full Text] [Related]
8. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients.
Kurata K; Yakushijin K; Okamura A; Yamamori M; Ichikawa H; Sakai R; Mizutani Y; Kakiuchi S; Miyata Y; Kitao A; Kawamoto S; Matsuoka H; Murayama T; Minami H
Cancer Chemother Pharmacol; 2018 May; 81(5):839-846. PubMed ID: 29511796
[TBL] [Abstract][Full Text] [Related]
9. A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation.
Gota V; Purohit V; Gurjar M; Nayak L; Punatar S; Gokarn A; Bonda A; Bagal B; Vora CS; Patil A; Nookala M; Khattry N
Cell Transplant; 2020; 29():963689720912925. PubMed ID: 32495641
[TBL] [Abstract][Full Text] [Related]
10. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation.
Jenke A; Renner U; Richte M; Freiberg-Richter J; Platzbecker U; Helwig A; Thiede HM; Schäfer-Eckart K; Ehninger G; Bornhäuser M
Clin Transplant; 2001 Jun; 15(3):176-84. PubMed ID: 11389708
[TBL] [Abstract][Full Text] [Related]
12. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
13. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
14. Influence of Calcineurin Inhibitors and Genetic Polymorphism of Transporters on Enterohepatic Circulation and Exposure of Mycophenolic Acid in Chinese Adult Renal Allograft Recipients.
Sun SS; Shao K; Lu JQ; An HM; Shi HQ; Zhou PJ; Chen B
J Clin Pharmacol; 2023 Apr; 63(4):410-420. PubMed ID: 36394393
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients.
Yoshimura K; Yano I; Yamamoto T; Kondo T; Kawanishi M; Isomoto Y; Yonezawa A; Takaori-Kondo A; Matsubara K
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1441-1448. PubMed ID: 29427741
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of EB virus infection between short term and long term use of mycophenolate mofetil for prophylaxis of graft versus host disease after haploidentical hematopoietic stem cell transplantation].
Yu CZ; Huang XJ; Xu LP; Liu KY; Zhang XH; Sun YQ; Liu JY; Zhao XY; Wang Y
Zhonghua Nei Ke Za Zhi; 2021 Sep; 60(9):806-811. PubMed ID: 34445816
[No Abstract] [Full Text] [Related]
17. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.
Minagawa K; Yamamori M; Katayama Y; Matsui T
Int J Hematol; 2012 Jul; 96(1):10-25. PubMed ID: 22592321
[TBL] [Abstract][Full Text] [Related]
19. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
Nakane T; Nakamae H; Yamaguchi T; Kurosawa S; Okamura A; Hidaka M; Fuji S; Kohno A; Saito T; Aoyama Y; Hatanaka K; Katayama Y; Yakushijin K; Matsui T; Yamamori M; Takami A; Hino M; Fukuda T
Int J Hematol; 2017 Apr; 105(4):485-496. PubMed ID: 27943166
[TBL] [Abstract][Full Text] [Related]
20. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
